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What is the best approach
for managing recurrent
bacterial vaginosis?
■ EVIDENCE-BASED ANSWER
The best way to prevent recurrent bacterial
vaginosis is to treat the initial episode with the
most effective regimen. Metronidazole (500 mg
orally twice daily for 7 days) has the lowest
recurrence rate among antimicrobial regimens
for bacterial vaginosis (20% vs 34%–50% for
other agents) (strength of recommendation
[SOR]: A). Women should be treated if they are
symptomatic (SOR: A), undergoing gynecologic
surgery (SOR: B), or at risk for preterm labor
(SOR: B).
When bacterial vaginosis recurs, providers
should confirm the diagnosis (Table 1) (SOR:
A), identify and control risk factors for recur-
rence (Table 2) (SOR: B), and consider other
causes while retreating bacterial vaginosis
(SOR: C). If the diagnosis is confirmed and
retreatment fails, consider suppression with
metronidazole 0.75% vaginal gel for 10 days
followed by twice weekly administration for 
4 to 6 months (SOR: C, trial ongoing). No 
evidence supports treating sexual partners or
administering oral or vaginal Lactobacillus 
acidophilus, but recolonization with vagina-
specific lactobacilli (L crispatus and L jensenii)
is undergoing Phase III clinical trials.
■ EVIDENCE SUMMARY
No trials have tested or compared specific, com-
prehensive strategies for recurrent bacterial vagi-
nosis. Given that bacterial vaginosis can also be
asymptomatic, recurrence often cannot be differ-
entiated from treatment failure. Accordingly,
recurrent bacterial vaginosis may be prevented by
using the most effective therapy for the initial
episode. A 2002 meta-analysis by the Centers for
Disease Control and Prevention’s (CDC) bacterial
vaginosis working group reviewed the indications
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toms is essential for diagnostic accuracy and treat-
ment for bacterial vaginosis (Table 1). 
For recurrent symptomatic bacterial vaginosis,
1 option is suppressive therapy with metronida-
zole gel 0.75%. After initial daily retreatment for
10 days, this can be used twice weekly for 4 to 6
months to decrease symptoms. This strategy is
based on expert opinion but is currently under-
going clinical trial.
One small crossover randomized controlled
trial of 46 women with bacterial vaginosis 
studied the consumption of live L acidophilus
cultures.5 Only 20 of the women had recurrent
for therapy and best treatments for bacterial vagi-
nosis.1 The group found 25 trials evaluating oral
metronidazole therapy involving 2742 women.
Although cure rates using either 500 mg twice
daily for 5 to 7 days or 2 g as a single dose were
similar at 2 weeks post follow-up (85%; range
67%–98%), the single-dose regimen led to higher
relapse rates 1 month after treatment (35%–50%
vs 20%–33%). 
Six trials enrolling 946 women assessed the
efficacy of various topical vaginal treatments.
Metronidazole gel, clindamycin cream, and clin-
damycin ovules had a wide range of initial cure
rates (50%–95%), but all had higher relapse
rates at 4 weeks than did oral metronidazole for
1 week (34%–49%).1 A more complete discus-
sion of the effectiveness of antibiotics for 
bacterial vaginosis can be found in a recent
Clinical Inquiry.2
The CDC reviewers identified causal relation-
ships between bacterial vaginosis and plasma-
cell endometritis, postpartum fever, and posthys-
terectomy vaginal-cuff cellulitis. They therefore
concluded it is reasonable to try to prevent post-
procedure infections by treating women who have
asymptomatic bacterial vaginosis before hys-
terectomy or pregnancy termination. Although
bacterial vaginosis has been associated with
preterm labor, trials evaluating treatment of bac-
terial vaginosis to prevent preterm delivery are
conflicting. A Cochrane review of bacterial vagi-
nosis and preterm labor suggests treating women
at high risk for preterm birth may reduce the risk
of low birthweight and preterm prelabor rupture
of membranes.3
Patients frequently try to self-diagnose vaginal
complaints and ask for treatments and retreat-
ments by phone. However, a prospective study of
253 women who underwent a structured tele-
phone interview and subsequent physical exam
found a poor correlation between telephone 
diagnosis and final clinical diagnosis (kappa 
coefficient of 0.12—very poor agreement).4
Accordingly, clinical and laboratory evaluation of
vaginal discharge and especially recurrent symp-
Amsel criteria for diagnosis 
of bacterial vaginosis
Patient must have 3 of the 4 criteria 
for diagnosis.
1. pH >4.5 (most sensitive)
2. Clue cells >20% (most specific)
3. Homogenous discharge
4. Positive whiff test (amine odor with addition
of KOH)
Source: Based on Amsel et al 1983.11
TA B L E  1
Risk factors 
for bacterial vaginosis
Use of vaginal foreign bodies, perfumed soaps,
or douching
Cigarette smoking
Intrauterine device
New male sexual partner
Sex with another woman
No condom use (trend toward association)
Source: Based on Marrazzo et al 20027; CDC 2002.8
TA B L E  2
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■ CLINICAL COMMENTARY:
Take a detailed history, make sure 
clinical findings support the diagnosis
Patients with recurrent bacterial vaginosis are
often embarrassed, frustrated, or angry with
the failure of prior medical therapy. Our chal-
lenge is to listen empathetically and avoid
blaming the patient for the failure. It is critical
to take another detailed history (again review-
ing sexual and perineal hygiene habits), con-
sider an expanded differential, and make sure
clinical findings continue to support the diag-
nosis. A discussion about the (current lack of)
evidence on pharmacologic therapy for recur-
rent cases must also be included in the visit. A
collaborative plan of action will help the
patient regain a sense of control over her
health.
Jon O. Neher, MD, Valley Medical Center, Renton, Wash
bacterial vaginosis. The groups were random-
ized to eat yogurt with and without live L aci-
dophilus cultures. While the results were
encouraging (50% reduction in episodes of 
bacterial vaginosis and increase in detectable
vaginal Lactobacillus), only 7 women actually
completed the study protocol.
Douching is the best-studied risk factor for 
bacterial vaginosis. A recent multicenter cross-
sectional study of 1200 women assessed douching
practices and found that recent douching increased
the risk of bacterial vaginosis twofold (odds
ratio=2.1; 95% confidence interval, 1.3–3.1).6
Evidence for the other risk factors listed in Table 2
is based on smaller studies or expert opinion.7,8
For women who continue to have recurrent or
unresolved vaginal symptoms not explained by
candidiasis or sexually transmitted infections
such as trichomoniasis, consider less common
causes such as atrophic vaginitis, chemical/
irritant vaginitis, allergic vaginitis, Behçets 
disease, desquamative interstitial vaginitis, or
erosive lichen planus vaginitis.9
■ RECOMMENDATIONS FROM OTHERS
No organizations have developed guidelines for
treating recurrent bacterial vaginosis. In 2002,
the Association for Genitourinary Medicine and
the Medical Society for the Study of Venereal
Diseases released national guidelines on the man-
agement of bacterial vaginosis,10 which generally
agrees with the previously described CDC recom-
mendations.
Grace A. Alfonsi, MD, Judith C. Shlay, MD,
MSPH, Denver Health and Hospital Authority, University of
Colorado Health Sciences Center; Sandi Parker, MLS,
Denison Memorial Library, University of Colorado Health
Sciences Center, Denver
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